NEWSROOM

THE LATEST NEWS ON THERMOSOME’S DEVELOPMENT

  • Posted 16. Juni 2017

Thermosome’s collaboration partner Philips publishes pre-clinical data of MR-HIFU mediated TSL-based drug delivery in PNAS

Researchers from Philips Research, Eindhoven University of Technology (The Netherlands) and University Hospital of Cologne (Germany) have published a joint scientific paper in the Proceedings of the National Academy of Science (PNAS), one of the world’s most prestigious scientific journals. The paper covers the use of MR-guided high intensity focused ultrasound (MR-HIFU) induced heating to […]
  • Posted 26. Mai 2017

Thermosome named as a 2017 Red Herring Top 100 Europe Winner

Thermosome GmbH, an emerging biopharmaceutical company, has been awarded as 2017 Red Herring Top 100 Europe Winner, recognizing Europe’s leading private companies and celebrating these startups’ innovations and technologies across their respective industries. Red Herring Top 100 Europe each year enlists outstanding entrepreneurs and promising companies. Red Herring selects the award winners each year from […]
  • Posted 6. Oktober 2016

Thermosome appoints Dr. Ulrich Grau, Dr. Jochen Knolle and Dr. Franz-Robert Klingan to its advisory board

Thermosome GmbH, an emerging biopharmaceutical company, today announces the appointment of Dr. Ulrich Grau, Dr. Jochen Knolle and Dr. Franz-Robert Klingan to its advisory board. Dr. Ulrich Grau has more than 35 years experience in the biopharmaceutical industry spanning from basic R&D functions to executive positions in Pharma and Biotech companies in Germany and the […]
  • Posted 15. September 2016

VDI Nachrichten profiles Thermosome’s technology and product focus

VDI Nachrichten, a weekly German newspaper with a focus on technology and science, featured Thermosome’s technology and product focus. While being applicable in various therapeutic areas, the article highlights Thermosome’s focus of its proprietary drug development, which lies on cancer patients with locally-advanced solid tumors. In these patients, Thermosome aims to either improve antitumor responses […]
  • Posted 10. September 2016

Thermosome article in Going Public special issue “Biotechnologie 2016”

Going Public features Thermosome in its special issue “Biotechnologie 2016” which comprised the most important developments in the German biotechnology industry in the year 2016. Besides others, it nicely distinguishes between traditional liposomes following a passive targeting approach using the enhanced permeability and retention (EPR) effect vs. thermosensitive liposomes (TSLs) following an active targeting approach […]
  • Posted 29. Juli 2016

Thermosome featured in Biotech magazine “IZB im Dialog”

The Biotech magazine “IZB im Dialog”, published by Germany’s largest Biotech cluster in Martinsried (near Munich), featured Thermosome’s technology, founder team and recent financing round in its 02/2016 edition published in July. Read more > (pdf)
  • Posted 6. April 2016

Thermosome raises €4.6m with first financing round and a research grant from the German government

Thermosome announces the closing of its first financing round, raising net proceeds of approximately €1.9 million from funds managed by High-Tech Gründerfonds Management GmbH and Bayern Kapital GmbH, respectively, as well as a group of private investors. This first financing round is substantially enlarged by a recently approved grant from the German Federal Ministry of […]
  • Posted 6. April 2016

Thermosome receives €2.7m research grant from the German Federal Ministry of Education and Research (BMBF)

Thermosome announces the final approval of a €2.7m grant from the German Ministry of Education and Research (BMBF) over the project duration of 3 years. The contribution to Thermosome is part of a larger project consortium called “TSL-LIFU”, consisting of Philips, the University Hospital of the Ludwig-Maximilians-Universitaet Munich (KUM) and the University Hospital Cologne (UHC). […]